5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The United States Drug Delivery Devices market is expected to register a CAGR of nearly 22.78% during the forecast period. The report is segmented by Route of Administration (Topical, Injectable, Oral and Others) and by Application.
The United States Drug Delivery Devices market is expected to register a higher CAGR during the forecast period. The factors such as growing burden of chronic diseases and the developments with respect to the druge delivery methods is expected to significantly contriute in the market growth. Accoding to the data of Centre for Disease Control and Prevention, about 6 out ten American individuals are suffering from one or the other chronic diseases. The changing lifestyle such as physical inactivity, consumption of high sugar diet, alcohol, smoking, etc. is responsible for the growing burden of the disease in the United States. According to the Centre for Disease Control and Prevention, 2020, the physical inactivity ranges between 17.3 to 47.7 in the country. Thus, it is expected to drive the need for management of these diseases and thereby thrive the United States Drug Delivery Devices market. However, recalling of the products by the Food & Drug Administration is expected to impede the market growth.
As per the scope, Drug delivery devices or system are the tools which are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. United States Drug Delivery Devices Market is segmented By Route of Administration and Application.
|By Route of Administration|
|By End Users|
|Ambulatory Surgical Centres|
Report scope can be customized per your requirements. Click here.
Cancer is expected to hold a major market share in the Application segment in USA Drug Delivery Devices Market growth. Cancer is one of the leading cause of death in the United States. According to the American Cancer Society, 2020, about 1.8 million new cancer cases are expected to register along with 606,520 cancer deaths in the United States. There is an immense need for a better delivery systems in the treatment of cancer in order to improve the outcome. Recent develpments with respect to the drug delivery system in cancer is further expected to accelerate the market growth. For instance, in October 2019, a group of researchers from Washington State University and the Department of Energy's Pacific Northwest National Laboratory (PNNL) developed a drug delivery technology for cancer treatment. They used peptoids tubes to deliver cancer-killing drugs in a targeted manner and results showed that it was enabled to track the efficiency of drug delivery into the cancerous cells. Thus, it is expected to show a tremendous growth during the forecast period.
To understand key trends, Download Sample Report
The key players in the United States Drug Delivery Devices market are Bayer AG, Johnson & Johnson Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Merck & Co. Inc., Sanofi, Abbott Laboratories and 3M. Companies are developing new products in to grow their presence in the market. In March 2019, CURE Pharmaceutical, expanded its oral drug delivery product line, creating CUREform, which includes CUREfilm, an advanced oral thin film.
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Chronic Diseases
4.2.2 Innovation in Drug Delivery Devices
4.3 Market Restraints
4.3.1 Product Recalls
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Route of Administration
5.2 By Application
5.3 By End Users
5.3.2 Ambulatory Surgical Centres
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Johnson & Johnson Inc.
6.1.3 Novartis AG
6.1.4 Pfizer Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 GlaxoSmithKline Plc
6.1.7 Merck & Co. Inc.
6.1.9 Antares Pharma
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments